Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses (Tables)

v3.7.0.1
Acquisitions, Investments and Licenses (Tables)
3 Months Ended
Mar. 31, 2017
Business Acquisition [Line Items]  
Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments
The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March 31, 2017:
(in thousands)
 
 
 
 
Investment type
 
Investment Carrying Value
 
Underlying Equity in Net Assets
Equity method investments
 
$
29,565

 
$
23,693

Variable interest entity, equity method
 
48

 

Available for sale investments
 
3,992

 
 
Cost method investment
 
608

 
 
Warrants and options
 
3,072

 
 
Total carrying value of investments
 
$
37,285

 
 
Transition Therapeutics  
Business Acquisition [Line Items]  
Purchase Price Allocation
The purchase price allocation for Transition Therapeutics is preliminary pending completion of the fair value analysis of acquired assets and liabilities:
(In thousands)
 
Transition Therapeutics
Cash and cash equivalents
 
$
15,878

IPR&D assets
 
41,000

Goodwill
 
3,453

Other assets
 
634

Accounts payable and other liabilities
 
(1,035
)
Deferred tax liability
 
(1,400
)
Total purchase price
 
$
58,530